Analysis of scientific publications related to Hepatitis B prevention in the last decade: 2013-2023

Autores

  • Anoucheka Julien Universidade Estadual do Pernambuco (UPE), Programa de Pós-graduação em Enfermagem. Recife, Pernambuco, Brasil
  • Antonio Rosa de Sousa Neto Universidade Federal do Piauí (UFPI), Programa de Pós-Graduação em Enfermagem. Teresina, Piauí, Brasil
  • Ana Raquel Batista de Carvalho Universidade Federal do Piauí (UFPI), Programa de Pós-Graduação em Enfermagem. Teresina, Piauí, Brasil
  • Daniela Reis Joaquim de Freitas Universidade Federal do Piauí (UFPI), Programa de Pós-Graduação em Enfermagem. Teresina, Piauí, Brasil
  • Luana Kelle Batista Moura Universidade de Ribeirão Preto – UNAERP, Programa de Pós-graduação em Odontología. Ribeirão Preto, São Pauli, Brasil. Faculdade de Tecnologia de Teresina – CET. Teresina, Piauí, Brasil
  • Maria Eliete Batista Moura Universidade Federal do Piauí (UFPI), Programa de Pós-Graduação em Enfermagem. Teresina, Piauí, Brasil
  • Simone Maria Muniz da Silva Bezerra Universidade Estadual do Pernambuco (UPE), Programa de Pós-graduação em Enfermagem. Recife, Pernambuco, Brasil
  • Rosilane de Lima Brito Magalhães Universidade Federal do Piauí (UFPI), Programa de Pós-Graduação em Enfermagem. Teresina, Piauí, Brasil

DOI:

https://doi.org/10.26694/repis.v10i1.5494

Palavras-chave:

Hepatitis B, Infectious Disease Transmission, Vertical, Sexually Transmitted Diseases, Communicable Disease Control

Resumo

Introduction: The World Health Organization estimates that chronic infection with the Hepatitis B Virus globally affects approximately 296 million individuals, with 1.5 million new infections yearly. Those affected often remain asymptomatic for extended periods but may inadvertently transmit Hepatitis B Virus to others. Aim: To analyze scientific publications related to the prevention of hepatitis B from 2013 to 2023. Outlining: A bibliometric study with a quantitative approach analyzing 333 articles using the Bibliometrix R package and its web interface Biblioshiny. Results: Articles were predominantly published in 2018 and 2019, with the Journal of Viral Hepatitis being the primary scientific journal. These articles were authored by 2,467 individuals from 810 institutions, emphasizing Udice - French Research Universities. Among the 81 countries identified, China figured prominently. The articles accumulated a total of 8,964 citations. The KeyWords Plus™ highlighted a focus on infection and its transmission pathways, notably vertical/perinatal, immunization against infection, and treatment using antiretrovirals. Implications: The need for new studies focused on educational interventions related to hepatitis B prevention was identified, including the creation, application, and evaluation of educational technologies.

Referências

World Health Organization (WHO). Hepatite B. 2023. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b. Accessed in 2023 (Dec 28).

Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560–99. PMID: 29405329; https://doi.org/10.1002/hep.29800.

Centers for Disease Control and Prevention (CDC). Viral Hepatitis: Hepatitis B Information. https://www.cdc.gov/hepatitis/hbv/index.htm. Accessed in 2023 (Dec 28).

Ministério da Saúde (BR). Secretaria de Vigilância em Saúde e Ambiente. Boletim epidemiológico: Hepatites Virais. 2023. Available from: https://www.gov.br/aids/pt-br/central-de-conteudo/boletins-epidemiologicos/2023/hepatites-virais/boletim-epidemiologico-hepatites-virais-_-2023.pdf/view. Accessed in 2023 (Dec 28).

Ministério da Saúde (BR), Secretaria de Vigilância em Saúde, Departamento de DST, Aids e Hepatites Virais. Protocolo Clínico e Diretrizes Terapêuticas para Hepatite B e Coinfecções. 2017. Available from: https://www.gov.br/saude/pt-br/assuntos/saude-de-a-a-z/h/hepatites-virais/publicacoes/protocolo-clinico-e-diretrizes-terapeuticas-para-hepatite-b/view. Accessed in 2023 (Dec 28).

Ministério da Saúde (BR), Secretaria de Vigilância em Saúde, Departamento de Doenças de Condições Crônicas e Infecções Sexualmente Transmissíveis. Protocolo Clínico e Diretrizes Terapêuticas para Atenção Integral às Pessoas com Infecções Sexualmente Transmissíveis – IST. 2022. Available from: https://www.gov.br/aids/pt-br/central-de-conteudo/pcdts/2022/ist/pcdt-ist-2022_isbn-1.pdf/view. Accessed in 2023 (Dec 28).

Vivaldini SM, Pinto FKA, Kohiyama IM, Almeida EC, Mendes-CorreaII MCJ, Santos AF, et al. Exploratory spatial analysis of HBV cases in Brazil between 2005 and 2017. Rev Bras Epidemiol (São Paulo). 2019;22(1):e190007. PMID: 31576983; https://doi.org/10.1590/1980-549720190007.supl.1.

Nuwarda RF, Ramzan I, Weekes L, Kayser V. Vaccine Hesitancy: Contemporary Issues and Historical Background. Vaccines (Basel). 2022;10(10):1595. PMID: 36298459; https://doi.org/10.3390/vaccines10101595.

Zupic I, Cater T. Bibliometric methods in management and organization. Organ Res Methods. 2015;18(3):429–472; https://doi.org/10.1177/1094428114562629.

Moura MEB, Neto ARS, Chissamba RE, Carvalho ARB, Peres NVG, Oliveira TA, et al. Global trends from original research on COVID-19 and coinfection. Rev Prev Infec e Saúde. 2023;8(1):4208. https://doi.org/10.26694/repis.v8i1.4208.

Carvalho ARB, Sousa Neto AR, Silva MDFD, Freitas DRJ, Moura MEB. Global research trends related to coronavirus disease 2019 and the aged: a bibliometric analysis. Sao Paulo Med J. 2023;142(2):e2022662. PMID: 37556683; https://doi.org/10.1590/1516-3180.2022.0662.R1.190523

Posit team. RStudio: Integrated Development Environment for R. 2023. Posit Software, Boston, Massachusetts; http://www.posit.co/.

R Core Team. R: A Language and Environment for Statistical Computing. 2023. R Foundation for Statistical Computing, Vienna, Austria; https://www.R-project.org/.

Aria M, Cuccurullo C. bibliometrix: An R-tool for comprehensive science mapping analysis. J Informetr. 2017;11(4):959-75. https://doi.org/10.1016/j.joi.2017.08.007.

Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383-403. PMID: 29599078; https://doi.org/10.1016/S2468-1253(18)30056-6.

Schillie S, Vellozzi C, Reingold A, Harris A, Haber P, Ward JW, et al. Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2018;67(1):1-31. PMID: 29939980; https://doi.org/10.15585/mmwr.rr6701a1.

Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):215-9. PMID: 25447850; https://doi.org/10.1053/j.gastro.2014.10.039.

Pan CQ, Duan Z, Dai E, Zhang S, Han G, Wang Y, et al. Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load. N Engl J Med. 2016;374(24):2324-34. PMID: 27305192; https://doi.org/10.1056/NEJMoa1508660.

Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):221-244.e3. PMID: 25447852; https://doi.org/10.1053/j.gastro.2014.10.038.

Cui F, Shen L, Li L, Wang H, Wang F, Bi S, et al. Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China. Emerg Infect Dis. 2017;23(5):765-772. PMID: 28418296; https://doi.org/10.3201/eid2305.161477.

Jourdain G, Ngo-Giang-Huong N, Harrison L, Decker L, Khamduang W, Tierney C, et al. Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B. N Engl J Med. 2018;378(10):911-923. PMID: 29514030; https://doi.org/10.1056/NEJMoa1708131.

Chang MH, You SL, Chen CJ, Liu CJ, Lai MW, Wu TC, et al. Long-term Effects of Hepatitis B Immunization of Infants in Preventing Liver Cancer. Gastroenterology. 2016 Sep;151(3):472-480.e1. PMID: 27269245; https://doi.org/10.1053/j.gastro.2016.05.048.

Huang H, Li X, Zhu J, Ye S, Zhang H, Wang W, et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. JAMA. 2014;312(23):2521-30. PMID: 25514302; https://doi.org/10.1001/jama.2014.15704.

Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH; American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261-83. PMID: 26566064; https://doi.org/10.1002/hep.28156

Liu Z, Chen Z, Cui F, Ding Y, Gao Y, Han G, et al. Management Algorithm for Prevention of Mother-to-child Transmission of Hepatitis B Virus (2022). J Clin Transl Hepatol. 2022;10(5):1004-10. PMID: 36304493; https://doi.org/10.14218/JCTH.2022.00047.

Yin J, Liang P, Chen G, Wang F, Cui F, Liang X, et al. Tenofovir prophylaxis for preventing mother-to-child hepatitis B virus transmission in China: A cost-effectiveness analysis. Int J Infect Dis. 2020;95:118-24. PMID: 32205288; https://doi.org/10.1016/j.ijid.2020.03.036.

Zhang W, Xu C, Rui Y, Chen J, Chen T, Dai Y, et al. Efficacy of the hepatitis B vaccine alone in the prevention of hepatitis B perinatal transmission in infants born to hepatitis B e antigen-negative carrier mothers. J Virus Erad. 2022;8(2):100076. PMID: 35813576; https://doi.org/10.1016/j.jve.2022.100076.

Yin J, Liang P, Chen G, Wang F, Cui F, Liang X, et al. Tenofovir prophylaxis for preventing mother-to-child hepatitis B virus transmission in China: A cost-effectiveness analysis. Int J Infect Dis. 2020;95:118-24. PMID: 32205288; https://doi.org/10.1016/j.ijid.2020.03.036.

Cressey TR, Harrison L, Achalapong J, Kanjanavikai P, Patamasingh Na Ayudhaya O, Liampongsabuddhi P, et al. Tenofovir Exposure during Pregnancy and Postpartum in Women Receiving Tenofovir Disoproxil Fumarate for the Prevention of Mother-to-Child Transmission of Hepatitis B Virus. Antimicrob Agents Chemother. 2018;62(12):e01686-18. https://doi.org/10.1128/AAC.01686-18.

World Health Organization (WHO). Hepatitis: Elimination of hepatitis by 2030. 2023. Available from: https://www.who.int/health-topics/hepatitis/elimination-of-hepatitis-by-2030#tab=tab_1. Accessed in 2023 (Dec 29).

Rizvi DS. Health education and global health: Practices, applications, and future research. J Educ Health Promot. 2022 Aug 25;11:262. PMID: 36325224; https://doi.org/10.4103/jehp.jehp_218_22.

Publicado

2024-02-28

Como Citar

Julien, A. ., Sousa Neto, A. R. de ., Carvalho, A. R. B. de ., Freitas, D. R. J. de ., Moura, L. K. B. ., Moura, M. E. B. ., Bezerra, S. M. M. da S. ., & Magalhães, R. de L. B. . (2024). Analysis of scientific publications related to Hepatitis B prevention in the last decade: 2013-2023. Revista Prevenção De Infecção E Saúde, 10(1). https://doi.org/10.26694/repis.v10i1.5494

Artigos mais lidos pelo mesmo(s) autor(es)